iX Biopharma has high hopes for drug spin-off
After the planned HK listing of its pharmaceutical and medical cannabis business, the company will focus on nutraceuticals. BY JANICE HENG
CATALIST-LISTED iX Biopharma wishes investors would focus less on its current topline or bottom-line, and more on the potential of its products and patented technology.
This search for understanding investors is one reason it is looking to spin off its pharmaceutical and medicinal cannabis business for a listing in Hong Kong, said director of corporate affairs Yee Chia Hsing.
"The type of conversation that they have (in Hong Kong) is very different. They don't ask you about when you turn profitable ... They talk about your drug pipeline, they try to understand the size of the market."
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Top HSBC shareholder Ping An exploring ways to cut US$13 billion stake
Gazelle Ventures’ cash offer for No Signboard closes with 0.5022% valid acceptances
Dow briefly sprints past 40,000-mark on earnings boost, rate-cut bets
Goldman strikes US$43 billion investing deal for UPS pension funds
US: Wall Street opens nearly flat after CPI-driven rally
Blackstone to buy Priority Software stake in biggest Israel deal